AdAlta Ltd. (AU:1AD) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
AdAlta Ltd. (ASX:1AD) is set to showcase its innovative therapeutic developments at the 2024 ASCEPT, APFP & APSA Joint Congress in Melbourne. The company’s Senior Scientist, Dr. Jason Lynch, will discuss key findings from their Phase I clinical studies on AD-214, a promising treatment for fibrotic diseases that could offer more convenient and cost-effective therapy options. With significant interest from major pharmaceutical companies, AdAlta is poised to make impactful advancements in the treatment of chronic lung diseases.
For further insights into AU:1AD stock, check out TipRanks’ Stock Analysis page.